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We report on a phase II clinical trial to determine the effect of a 
concurrent ultra-fractionated radiotherapy and temozolomide treatment 
in inoperable glioblastoma patients. A phase II study opened; patients 
over 18 years of age who were able to give informed consent and had 
histologically proven, newly diagnosed inoperable diagnosed and 
supratentorial glioblastoma were eligible. Three doses of 0.75 Gy spaced 
apart by at least four hours were delivered daily, five days a week for six 
consecutive weeks for a total of 67.5Gy. Chemotherapy was administered 
during the same period, which consisted of temozolomide given at a dose 
of 75 mg/m2, for seven days a week. After a four-week break, 
chemotherapy was resumed for up to six cycles of adjuvant temozolomide 
treatment, given every 28 days, according to the standard five-day 
regimen. Tolerance and toxicity were the primary endpoints; survival and 
progression-free survival were the secondary endpoints. In total 40 
patients were enrolled in this study, 31 men and 9 women. The median 
age was 58 years, and the median Karnofsky performance status was 80. 
The concomitant ultra fractionated radiotherapy and temozolomide 
treatment was well tolerated. Complete responses were seen in four 
patients, and partial responses were reported in seven patients. The 
median survival from the initial diagnosis was 16 months. Several long-
term survivors were noted. Concurrent ultra-fractionated radiation 
therapy and temozolomide treatment is well accepted by the patients. The 
results showed encouraging survival rates for these unfavorable patients. 
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 INTRODUCTION 
 
Glioblastoma (GBM) is the most common primary brain tumor in 
adults and is characterized by a high rate of local recurrences because of its 
intrinsic radio resistance1-4. Indeed, GBM is considered one of the most radio 
resistant tumors1-4. After maximal surgical tumor resection as safe as 
possible, the current standard of care is based on a phase III randomized 
trial from the EORTC / NCIC1-5. This treatment comprises a concurrent 
combination of conformational brain radiotherapy (RT) and chemotherapy 
using temozolomide (TMZ), followed by a four-week break and adjuvant 
chemotherapy with TMZ for up to six cycles1-5. Despite the improvement in 
outcome with the new standard regimen, the median overall survival (OS) 
does not exceed 15 months; therefore, new therapeutic strategies are 
needed1-5. 
 
Conformational RT remains the backbone of care for GBM. Although 
RT is not a curative treatment for GBM, it results in a longer survival rate 
and optimized quality of life6. It is unclear whether clinical radio resistance 
in GBM is a result of intrinsic resistance at the cellular level. The 
mechanisms involved in radiation resistance in mammalian cells are more 
complex than once believed7. In vitro studies have shown that some human 
tumor cell lines are sensitive to low radiation doses of <1 Gy, a phenomenon 
that has been termed low-dose hypersensitivity (HRS)8-17. Strikingly, this 
“radio-sensitivity” is more apparent in radio resistant cell lines, such as 
glioma cells8-17. We demonstrated this phenomenon in a number of various 
human malignant glioma cell lines using a common clinical device for 
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irradiation7,17. Daily repeated irradiation of cells with low doses compared 
with irradiation with a single biologically equivalent dose resulted in 
significantly higher cell death (using a clonogenic assay)7,17. Experiments 
conducted on glioma xenografts revealed that repeated irradiation with low 
doses (0.8 Gy, three times a day) is more effective than a single dose (2 or 
2.4 Gy, once a day) in inhibiting tumor growth7,17. 
 
Consequently, in 2003 we began a phase II study testing an ultra 
fractionated RT for inoperable de novo GBM18. The results were promising, 
and are comparable with the results using the TMZ/RT treatment from the 
EORTC/NCIC trial. However, in the ultra-fractionated RT trial, there were only a 
few long-term survivors that was unexpected since these types of patients 
have an unfavorable prognosis (a survival expected at least 10 months), the 
rate of two-years survival was 15.48%18. These data suggested that the 
combination of ultra fractionated radiation therapy and concomitant and 
adjuvant TMZ chemotherapy (combination radiotherapy and chemotherapy 
is the standard) should be more efficient. Here, we report the results of a 
second phase II trial that tested a concurrent combination of ultra 
fractionated brain irradiation (three-daily doses – five times a week for six 
consecutive weeks) and TMZ treatment followed by adjuvant TMZ therapy, in 
de novo inoperable GBM patients.  
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MATERIAL AND METHODS 
     
 PATIENTS: This phase II study was conducted in eight French centers. 
Patients were eligible for the study if they were at least 18 years old and had 
newly diagnosed, inoperable supratentorial GBM (based on neurosurgical 
criteria such as Rolando and/or callosum corpus or deep locations of tumor) 
that was histologically confirmed (astrocytoma grade IV according to the 
WHO classification). Additional inclusion criteria were a WHO performance 
status of 0–2; adequate hematologic; hepatic, and renal function; acceptable 
blood coagulation levels; and ability to give informed consent. Patients who 
had undergone a partial or complete tumor resection were not eligible. 
 
 TREATMENT: The RT regimen consisted of ultra-fractionated focal 
irradiation, with three daily doses of 0.75 Gy delivered at least four hours 
apart. Irradiation of the tumors was performed five days a week (Monday 
through Friday), for six consecutive weeks, resulting in 90 fractions and a 
total of 67.5 Gy of radiation. Irradiation was delivered to the gross tumor 
volume with a 2.5 cm margin for the clinical target volume. RT was planned 
with dedicated computed tomography or magnetic resonance imaging (MRI) 
and three-dimensional planning systems; conformal ultra-fractionated RT 
was delivered with linear accelerators with a nominal energy > 6 MeV. The 
patients were treated with thermo-plastic immobilization masks to ensure 
adequate immobilization and reproducibility. Chemotherapy consisted of 
TMZ treatment at a dose of 75 mg/m2/day, given seven days a week during 
the ultra-fractionated RT. After a four-week break, TMZ chemotherapy was 
resumed at 150-200 mg/m2/day, for up to six cycles every 28 days, in 
accordance with the EORTC trial. 
Page 5 of 26
  
 PATIENT EVALUATION: Patients were assessed weekly for tolerance 
and toxicity during the RT. The baseline examination included a cranial MRI 
(with and without contrast), physical and neurologic examinations, Mini-
Mental-Status score (MMS) and a quality of life questionnaire (EORTC—
QLQ-C30, Brain Cancer Module BN-20). A baseline examination was 
performed at the end of the RT regimen (within the first 10 days after 
completion of the ultra-fractionated irradiation) and then every two months 
until death. The first MRI (at the end of RT) was the baseline imaging used to 
evaluate the tumor response, keeping in mind that RT artifacts could be 
present and should be considered in the interpretation of the MRI. Tumor 
progression was defined according to the modified WHO criteria (Macdonald 
criteria) as a 25 % increase in tumor size (size of the product of the largest 
perpendicular diameters of the contrast-enhanced tumor), the appearance of 
new lesions, or an increased need for corticosteroids19. When tumor 
progression was found, patients were treated at the investigator’s discretion, 
and the type of subsequent therapy (usually chemotherapy) was recorded. 
 
 MGMT ANALYSIS: DNA was extracted from FFPE samples, directly 
followed by bisulfite conversion using the EpiTect Fast Bisulfite Conversion 
Kit. Pyrosequencing was performed with the PyroMark Q96 MGMT kit on a 
PSQTM96 MA system, as previously described20. All the reagents were from 
Qiagen; Courtaboeuf, France. For data analysis, the average percentage of 
the five CpGs was determined and the cutoff set à 8% 20 
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 STATISTICAL METHODS: The primary end points of the study were to 
document the treatment-related toxicity and tolerance of all patients treated 
with this novel regimen. The secondary end points were the progression-free 
survival (PFS) and OS reported as an intent-to-treat analysis on all 40 
patients included. Survival times were calculated from the date of the initial 
diagnosis (date of stereotactic biopsy) to the date of death, progression, or 
last follow-up. The Kaplan–Meier technique was used to compute the 
estimates for PFS and OS parameters and their 95% confidence intervals 
(CI). SPSS statistical software (SPSS, Inc.) was used for the primary 
analyses. SAS v 9.1.3 (SAS Institute, Inc.) was the statistical software used 
by the EORTC for the survival analyses. To estimate the efficacy of the ultra-
fractionationed therapy (TEMOFRAC) on patients, we compared our results 
with the subgroup of patients that underwent only a biopsy and who were 
treated within the EORTC/NCIC 26981-22981/CE.3 trial. This randomized 
trial established the combination of standard RT and concomitant treatment  
and maintenance with temozolomide chemotherapy (TMZ/RT) compared 
with once daily fractionated RT alone. A Kaplan-Meier curve, log-rank test, 
and Cox regression were used at an exploratory 5% significance to assess 
the effects of TEMOFRAC compared to RT or TMZ/RT, with and without 
adjustment for possible confounding effects. Available factors were age and 
WHO performance status. MMSE scores were collected in only about half of 
the patients and were not included. MGMT data were missing in 91% of the 
cases for each arm of EORTC/NCIC trial. Adjusted hazard ratios (HR) were 
computed with 95% CI. Survival analyses were performed in the intent-to-
treat population. P-values in figures are from unadjusted analyses, and 
adjusted values are given in the text. 
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RESULTS 
 
 PATIENT CHARACTERISTICS: From July 2008 until July 2011, 40 
patients were enrolled in this phase II study; there were 29 males and 11 
females. Five patients were diagnosed with multifocal GBM. Three sudden 
deaths (probably due to pulmonary embolism or myocardial infarction) and 
three deaths unrelated to GBM (two pulmonary infections and one grade 4 
hematological toxicity with severe sepsis) were reported in our series, so, 
thirty-four patients were finally included for the analysis (Table 1). The 
median age of the population was 59 years old, and ranged from 29.1  - 
73.5, 14 patients were aged from > 50 to < 60, 18 were > 60, and 10 were > 
70 years old. Twenty-six patients had a performance status of < 1, and 14 
patients had a performance status of 2.  
 
 
 TREATMENT DELIVERY SAFETY AND TOLERABILITY: All of the 40 
patients underwent and completed the ultra-fractionated irradiation and 
TMZ treatment. No disruptions in the concomitant chemotherapy were 
reported. The treatment was delivered on an inpatient basis, five days of 
hospitalization per week for six consecutive weeks. Although this ultra-
fractionated irradiation could have cause side effects, this regimen was well 
tolerated by the patients. The most common adverse event was fatigue, 
which is usually noted in standard cranial RT. The main adverse effects 
reported were: 
- Fatigue, grade II in 30 patients, 
- Alopecia, grade II in 20 patients, 
- Skin reaction, grade I in 10 patients, 
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- Headache, grade I in 6 patients, 
- Nausea and seizures were not reported 
TMZ was administered concomitantly in all of the patients, and adjuvant 
chemotherapy (six cycles of TMZ) was completed in 26 patients (76.4%). Two 
patients developed a pulmonary infection and one patient presented grade 4 
hematological toxicity; these were all fatal (Table 2).  
 
 MGMT STATUS: The MGMT promoter analysis was only performed in 
23 patients; the data were missing in the remaining 11 cases. The MGMT 
promoter was found methylated in 12 of the patients (52.2%), and 
unmethylated in the last 11 patients (47.8%). Due to some data missing (32 
%), no statistical analysis was allowed. In the case of the EORTC/NCIC trial, 
MGMT data were documented in less than 10% of the cases. However, we 
noted a high rate of longer OS within the patients with a methylation of 
MGMT promoter (8 patients of 12 with MGMT methylated had a OS > 19 
months).                                                                                   
 
 EFFICACY OUTCOMES: The median follow-up of this trial was four 
years. Three of the patients are currently still alive (8.8%), and 31 patients 
are dead (91,2%). The median OS was 16 months (15.92; 95% CI 9.7-22.6) 
in the analyzed population; the two-year survival rate was 32.4% (95% CI 
17.6%-48.0%), the three-year 17.2% (95% CI 6.7%-31.6%) and the four-year 
rate was 9.2 % (95% CI 2.0%-23.3%). The Median PFS was 9.6 months (95 
% CI 7.2-12.12), and the PFS rate at six months was 76.5% (95% CI 2.0%-
23.3%). The tumor response was analyzed; four complete responses were 
reported, and seven partial responses were noted. Three patients progressed 
during the irradiation schedule. The quality of life questionnaire (EORTC—
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QLQ-C30, Brain Cancer Module BN-20) was completed by only a minority of 
the patients; therefore, we did not pursue any further analysis. When tumor 
progression was observed, the patients were treated at the physician’s 
discretion. The response to salvage therapy was not recorded, but an 
association, including bevacizumab agent, was diffusely used. 
 
COMPARISON WITH THE EORTC/NCIC TRIAL: We compared our results 
with those obtained during the EORTC/NCIC trial on patients who only had 
a biopsy. The RT arm included 45 patients, the TMZ/RT arm had 48 
patients and the TEMOFRAC group from this study included 34 patients. 
The median and two-year OS for the RT arm and the RT/TMZ arm of the 
EORTC/NCIC trial were 8.7 months (95% CI 6.3-11.0) and 4.6% (95% CI 
0.8%-13.7%) and 10.2 months (95% CI 7.3-14.1) and 10.4% (95% CI 3.8%-
20.9%), respectively (Table 3 and 4). The median PFS in the RT group and 
RT/TMZ group was 5.0 (95% 3.2-5.9) and 6.0 (95% CI 5.0%-8.8%) months 
respectively. 
- TEMOFRAC versus EORTC/NCIC RT: In the PFS and OS analyses, 
TEMOFRAC showed a significant difference for an improved outcome 
over EORTC/NCIC RT (adjusted PFS: p < .0001, HR 0.46 (95% CI 
0.34 – 0.61) and adjusted OS: p = 0.0002 HR 0.62 (95% CI 0.48–0.80) 
(Fig.1). 
 
- TEMOFRAC versus EORTC/NCIC RT/TMZ: Again, an improvement in 
the outcome for PFS and OS was reported for TEMOFRAC versus 
RT/TMZ (adjusted PFS: p = 0.047, HR 0.62 (95% CI 0.39–0.99) and 
adjusted OS p = 0.0184, HR 0.57 (95% CI 0.35–0.91) (Fig. 2). 
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DISCUSSION 
RT remains the standard of care for GBM and has an undisputed 
major benefit on survival5,21-23. Currently, concomitant and adjuvant TMZ 
chemotherapy during RT is the standard of care for adult GBM patients aged 
up to 70 years old and in good general and neurological condition; however, 
the OS for unresected GBM (biopsy) remains low, approximately 10 months5. 
Despite their high inherent radio-resistance, and survival fraction at 2 Gy, 
GBM tumors receive the same dose per fraction, similar total dose and 
equivalent overall duration of RT as others tumors considered less 
radiosensitive, such as breast tumors21-23. In the past decade, many drugs 
have been developed to improve the outcome of GBM patients, but novel 
approaches to the RT regimen have been ignored, except for the development 
of the ballistic and intensity-modulation radiation therapy techniques 
(IMRT)21-24. In the past, alternative regimens of radiotherapy utilizing 
fractionation were proposed based on the hypothesis that radiation therapy 
could be improved by increasing total dose or decreasing overall time of 
treatment25-30. These regimens are called “hyper fractionation” (the dose per 
fraction is decreased, the number of fractions increased, the total dose is 
increased, and the total treatment time remains similar to conventional 
therapy time) or “accelerated fractionation schedules” (the total dose and 
dose per fraction remain unchanged, but the number of fractions per day is 
increased and thus the overall treatment time is reduced and treatment 
intensity increased). Hyper fractionation exploits the difference in 
fractionation sensitivity between tumors and normal tissues manifesting late 
morbidity. In contrast, accelerated fractionations attempt to reduce tumor 
proliferation as a major cause of radiotherapy failure25-30. A few hyper 
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fractionated or accelerated regimens of RT were tested on GBM patients, but 
all of the studies failed to demonstrate any improvement in the OS rate, and 
moreover, some neurological toxicity was reported25-30.  
 
 
Our previous studies, especially the in vitro ones showed that daily 
repeated low-dose irradiation of cells, compared to a single biologically 
equivalent dose, resulted in significantly higher cell death7,17. Experiments 
conducted on glioma xenografts demonstrated that repeated low-dose 
irradiation was more effective for inhibiting tumor growth than a single large 
dose7,17. The exact mechanisms underlying HRS are not clear. The 
demonstration of marked HRS in some human radio resistant tumors 
suggests that inducible repair might be an important component of the radio 
resistance that is apparent in these tumors at high doses. Radio resistance 
may only occur when there is enough initial damage or accumulated damage 
to trigger DNA repair mechanisms, which are more efficient than the 
constitutive DNA maintenance functions. Therefore, so-called induced radio 
resistance may occur only after relatively large doses but not at doses below 
a certain threshold. 
 
This low-dose hypersensitivity (HRS) phenomenon seemed to provide 
a new promising and effective treatment for GBM patients; clinical trials 
were performed to confirm its benefit7,17. Our first clinical study (ULTRA-RT), 
which tested ultra-fractionated RT in de novo, inoperable GBM patients 
showed that this regimen was safe and well tolerated18. However, the OS was 
only 9.53 months, which is comparable with the survival rate reported in the 
literature for these unresectable GBM18. Interestingly, an increased number 
Page 12 of 26
of long survivors were reported (two-years survival was 15.48 %)18. 
TEMOFRAC is the first trial to explore the effects of a combined fractionated 
low-dose radiation therapy and TMZ as a first-line treatment for inoperable, 
de novo GBM patients. The expected low-dose hypersensitivity was observed 
after the ultra-fractionated RT and TMZ treatments, and an additive effect 
was suggested. The TEMOFRAC clinical trial confirmed that fractionated 
low-dose RT is feasible, can be performed daily and is well accepted by 
patients. However, this ultra fractionated regimen could be lived by the 
patient as more binding that the standard treatment, for a little gain of 
survival. 
It is noteworthy that four complete responses and seven partial 
responses were reported in our series; to the best of our knowledge, this type 
of response has never been reported with RT for GBM patients1-6,21-23. 
Moreover, TMZ used in conjunction with RT and as an adjuvant regimen did 
not show a similar range of responses5,24. Therefore the combination of ultra-
fractionated RT and TMZ could explain this unusual high rate of response 
rate in our study. Unfortunately, the toxicity in our trial was higher than 
expected and similar to that reported with concomitant RT and TMZ 
treatment in the literature; two fatal pulmonary infections and a grade 4 
hematological toxicity with a major sepsis, also fatal. At the beginning of the 
study, prophylactic treatment for pneumocystis lung infection was not 
recommended; the absence of prophylaxis could explain the two fatal 
pulmonary infections. Although, the hematological toxicity from the TMZ 
was considered moderate, it can be severe5,24. The unusual toxicity reported 
in our series suggested that ultra fraction regimen plus TMZ is not as safe as 
expected for this type of combination of therapies5,24. The dose per fraction is 
correlated to the tolerance to RT as reported in our previous ULTRA-RT 
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clinical trial ULTRA-RT, neurological symptomatology evoking a post-RT 
leukoencephalopathy was not recorded. 
The results obtained for this group of GBM patients with unfavorable 
prognoses (biopsy only, class RPA V, some patients > 70 years old) are both 
surprising and promising. Taking into account our trial was a phase II study 
with only 34 patients and did not have a predictive factor such as MGMT 
status, our results displayed one of the longer OS rates reported for 
inoperable GBM patients. Moreover, they are better than those noted in 
EORTC/NCIC trial for unresected GBM patients5. The high rate of long-term 
survivors reported in the TEMOFRAC (32,4 % two-year survival and 17,6 % 
three-year survival) confirms the efficacy of this new regimen of RT5,24. GBM 
is a highly vascularized tumor that overexpresses vascular endothelial 
growth factor A (VEGF-A), a key regulator of tumor-associated 
angiogenesis23. Previous results from clinical trials support a role for the 
anti-VEGF-A molecule bevacizumab in recurrent and newly diagnosed 
GBM31. Two large phase III studies have recently been published that 
evaluated bevacizumab treatment in conjunction with RT and concomitant 
and adjuvant TMZ treatment as the first-line treatment for GBM – (AVAGLIO 
and RTOG 0825)32,33. Both trials showed a 3-4 month prolongation of the 
PFS with bevacizumab but without significant effects on the OS (AVAGLIO 
OS was 16.8 months in the bevacizumab arm and 16.7 months in the 
control arm; RTOG 0825 OS was 15.7 months in the bevacizumab group 
and 16.1 months in the control group). It is noteworthy that only 10 % of 
patients underwent a stereotactic biopsy in the AVAGLIO trial; at least 3 % 
underwent one in the RTOG study32,33. TEMAVIR, a French phase II 
randomized trial, was conducted to evaluate bevacizumab and irinotecan as 
neo-adjuvant and adjuvant treatments combined with TMZ chemo-radiation 
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for unresectable GBM; there were no differences found in the two arms for 
survival (OS was 11.1 months)31. Our results are significantly better than 
those from the TEMAVIR trial, and are comparable with those obtained from 
the AVAGLIO and RTOG 0825 trials31-33. 
In conclusion, this trial reported one of the longer OS rates for 
unresectable GBM, and the regimen is feasible for routine clinical practice, 
and well accepted by the patients. The combination of ultra-fractionated RT 
and TMZ given concomitantly and in an adjuvant schedule merits further 
evaluation especially in resected GBM patients. 
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TABLE 1 
Patient’s characteristics and survival status 
 
 
                              Treatment 
RT 
(N=45) 
TMZ/RT 
(N=48) 
TEMOFRAC 
(N=34) 
 N (%%) N (%%) N (%%) 
Extent of surgery: Biopsy                                                                                  
 
Sex 
 
Female              
Male  
 
 
MGMT                   
   45 (100.0)  
 
 
12 (26.7)  
33 (73.3) 
 
                                                                                              
48 (100.0) 
 
 
19 (39.6)               
29 (60.4)               
          34 (100) 
 
 
           10 (29.4)  
           24 (70.6)                                                                                                  
 unmethylated                    2 (4.4)                                                                                          3 (6.3)                                                                                          11 (32.4)                                           
 methylated                      2 (4.4)                                                                                          1 (2.1)               12 (35.3)                                                                  
 Missing                        41 (91.1)                                             44 (91.7)                                                                               11 (32.4)                                                 
Performance status                                                                                                                                                                                                         
 0                           14 (31.1)                                                                                         17 (35.4)                                                                     4 (11.8)                                       
 1                           24 (53.3)               22 (45.8)                                                                                         18 (52.9)                                                
 2                            7 (15.6)                                                                                         9 (18.8)                   12 (35.3)                                                                   
Age                                                                                                                                                                                                                           
 <=50 yrs                        0 (0.0)                                                                                          2 (4.2)                                                                         1 (2.9)                                            
 >50 & <=60 yrs                 32 (71.1)                                                                                         24 (50.0)                                                                    18 (52.9)                                          
 >60 yrs                        13 (28.9)                                                                                         22 (45.8)                                                                                      15 (44.1)    
 Median                                                                                                                       56.0   59.0     59.0              
 Range                                                                                                                        41.0 - 69.0    30.0 - 70.0 29.1 – 73.5      
  
 
Tumor location 
  
                  One lobe 
                  Multilobal 
                  Other/Missing 
 
PFS event 
 
                  No 
                  Yes 
 
Survival status 
 
                  Alive 
                  Dead 
 
                       
                                                                                                                             
 
 
 
 
29 (64.8) 
12 (26.7) 
4 (8.8) 
 
 
 
0 (0.0)  
45 (100.0) 
 
 
 
2 (4.4)        
43 (95.6) 
 
 
  
  
 
 
 
34 (70.9) 
14 (29.2) 
0 (0.0) 
 
 
 
 
  2 (4.2) 
       46 (95.8) 
 
 
          
       2 (4.2) 
       46 (95.8) 
 
 
 
                
 
 
 
 
 29 (85.3) 
5 (14.7) 
0 (0.0) 
 
 
 
 3 (8.8) 
    31 (91.2)  
 
 
 
 3 (8.8) 
    31 (91.2)           
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TABLE 2 
        Toxicities reported during the phase II Trial 
 
Type of 
Toxicity 
Number of 
patients 
Percentage 
Fatigue gde II 30 88 % 
Alopecia gde 
II 
20 58 % 
Skin reaction 
gde I 
10 29 % 
Headaches 
gde I 
6 17 % 
Pulmonary 
infection gde 
IV 
2 5 % 
Hematological 
toxicity gde 
IV 
1 2 % 
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TABLE 3 
 
Survival Time 
Treatment 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
P-Value 
(Log-Rank) 
Median (95% CI) 
(Months) 
% at 2 Year(s) 
(95% CI) 
RT                                     45         43 1.00                  0.0007 8.67 (6.31, 10.97)            4.60 (0.84, 13.74)  
TEMOFRAC         34         30 0.44 (0.27, 0.72)           15.92 (9.69, 22.60)           32.35 (17.62, 48.02) 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Treatment 1 -0.47940 0.13000 13.5997 0.0002 0.619 0.480 0.799 
WHO PS 1 0.18214 0.18955 0.9234 0.3366 1.200 0.827 1.740 
AGE 1 0.02304 0.01360 2.8709 0.0902 1.023 0.996 1.051 
 
 
 
Page 23 of 26
  
 
 
 
 
TABLE 4 
 
Survival Time 
Treatment 
Patients 
(N) 
Observed 
Events 
(O) 
Hazard Ratio 
(95% CI) 
P-Value 
(Log-Rank) 
Median (95% CI) 
(Months) 
% at 2 Year(s) 
(95% CI) 
RT                                     45         43 1.00                  0.0007 8.67 (6.31, 10.97)            4.60 (0.84, 13.74)  
TEMOFRAC         34         30 0.44 (0.27, 0.72)           15.92 (9.69, 22.60)           32.35 (17.62, 48.02) 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error Chi-Square Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Treatment 1 -0.47940 0.13000 13.5997 0.0002 0.619 0.480 0.799 
WHO PS 1 0.18214 0.18955 0.9234 0.3366 1.200 0.827 1.740 
AGE 1 0.02304 0.01360 2.8709 0.0902 1.023 0.996 1.051 
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